Volume 36, Issue 2 , Pages 137-144, August 2010
Exposure–response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria
Abstract
This study explored tigecycline exposure–bacterial responses in pharmacodynamic simulations (in vitro kinetic model) using different inocula. One meticillin-resistant vancomycin-heteroresistant Staphylococcus aureus, one Enterococcus faecium and one extended-spectrum β-lactamase-producing Escherichia coli with equal tigecycline minimum inhibitory concentrations/minimum bactericidal concentrations (MICs/MBCs) (0.12/0.25
μg/mL) were used. A computerised pharmacodynamic bicompartmental model simulated three tigecycline twice-daily dosing regimens over 48
h: 50
mg (100
mg loading dose); 100
mg; and 150
mg. Areas under bacterial growth curves were calculated, and differences between the growth curve used as control and the killing curve of bacteria exposed to tigecycline (ABBC) were determined. With standard inocula [ca. 1
×
106
colony-forming units (CFU)/mL], linear increases in area under the concentration–time curve (AUC)/MIC (25.6 for 50
mg, 53.76 for 100
mg and 79.52 for 150
mg) produced linear increases in activity against Gram-positive organisms (mean ABBCs of 120.60, 143.20 and 195.80
log
CFU
×
h/mL for S. aureus and of 95.75, 172.55 and 216.90
log
CFU
×
h/mL for E. faecium, respectively), with the activity of the 150
mg regimen being significantly higher (P
<
0.01) than that of the other two regimens. ABBCs obtained with the 100
mg regimen using standard inocula were similar to those obtained with the 150
mg regimen when using high inocula (ca. 1
×
107
CFU/mL). Against E. coli, the highest dosing regimen was required to obtain significant antibacterial activity compared with control (mean ABBCs of 145.75
log
CFU
×
h/mL with standard inocula and 63.33
log
CFU
×
h/mL with high inocula). An increase in tigecycline dosing appears to be an interesting therapeutic option to maximise antibacterial activity owing to its linear pharmacokinetics and pharmacodynamics, especially when severe infections with high bacterial load are suspected.
Keywords: Staphylococcus aureus, Enterococcus faecium, Glycylcyclines, Pharmacodynamics, Inoculum effect
To access this article, please choose from the options below
PII: S0924-8579(10)00154-8
doi:10.1016/j.ijantimicag.2010.03.021
© 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
Volume 36, Issue 2 , Pages 137-144, August 2010
